Hims & Hers uses FDA compounding loopholes to mass-produce knockoff drugs, adding vitamin B12 to claim personalization and evade patents.
They launched a Super Bowl ad criticizing Big Pharma’s pricing for semaglutide then partnered with Novo Nordisk, only to be dropped for continuing to sell unapproved Chinese-sourced compounded injections.
They repackaged dangerous, gas-station style erectile dysfunction pills combining sildenafil and tadalafil as “Hard Mints,” despite known medical risks.
Consumers pay inflated subscription fees for generic medications, locked into long-term auto-renewing plans with minimal medical oversight or live doctor interaction.
Hims’s telehealth model prioritizes conversion and convenience over genuine care, using brief questionnaires to instantly bill customers and making refunds difficult.
The broader direct-to-consumer telehealth industry similarly exploits regulatory good faith, selling unvetted compounds like sermorelin, BPC-157, and other peptides sourced from unapproved suppliers.
This ecosystem has corrupted trust in medicine by treating pharmaceuticals as retail products, extracting high premiums for inferior and potentially unsafe treatments.
Get notified when new stories are published for "General AI News"